Vistagen Therapeutics Inc
For the period ended Mar 31, 2025. Filed Jun 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Jun 17, 2025
VTGN$0.18-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(in thousands)
| Year Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(51,418) | $(29,362) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 150 | 127 |
| Loss on disposal of fixed assets | — | 6 |
| Stock-based compensation | 4,315 | 2,182 |
| Amortization of operating lease right-of-use asset | 485 | 441 |
| Accretion of marketable securities | (389) | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (88) | 250 |
| Other assets | 190 | — |
| Operating lease liability | (611) | (495) |
| Deferred sublicense revenue, net of deferred contract acquisition costs | (412) | 516 |
| Accounts payable and accrued expenses | 5,681 | 522 |
| Net cash used in operating activities | (42,097) | (25,813) |
| Cash flows from investing activities: | ||
| Purchases of laboratory and other equipment | (191) | (61) |
| Sales and maturities of marketable securities | 12,027 | — |
| Purchases of marketable securities | (24,984) | — |
| Net cash used in investing activities | (13,148) | (61) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock and warrants, net of issuance costs | — | 93,453 |
| Net proceeds from sale of common stock under Open Market Sale Agreement, net of deferred offering costs | 3,009 | 35,926 |
| Net proceeds from sale of common stock under Employee Stock Purchase Plan | 201 | 8 |
| Repayment of note payable | — | (985) |
| Net cash provided by financing activities | 3,210 | 128,402 |
| Net increase (decrease) in cash and cash equivalents | (52,035) | 102,528 |
| Cash and cash equivalents at beginning of period | 119,166 | 16,638 |
| Cash and cash equivalents at end of period | $67,131 | $119,166 |
| Supplemental disclosure of noncash activities: | ||
| Non-cash investing and financing activities: | ||
| Insurance premiums settled by issuing note payable | $— | $879 |
| Purchases of equipment included in accounts payable | $— | $29 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.